Hydrogenated Polyisobutene, Simmondsia Chinensis (Jojoba) Seed Oil, Octyldodecanol, Copernicia Cerifera (Carnauba) Wax / Copernicia Cerifera Cera / Cire De Carnauba, Tocopheryl Acetate, Cocos Nucifera (Coconut) Oil, Orbignya Oleifera (Babassu) Seed Oil, Prunus Armeniaca (Apricot) Kernel Oil, Acrylates Copolymer, Alumina, Aluminum Calcium Sodium Silicate, Calcium Aluminum Borosilicate, Calcium Sodium Borosilicate, Silica, Synthetic Fluorphlogopite, Tin Oxide, Polyethylene Terephthalate, Propylene Carbonate, Disteardimonium Hectorite, Ethylhexyl Hydroxystearate, Vanillin, Phenoxyethanol
In vivo , on the contrary to what was observed following the administration of bioactive end products (6-mercaptopurine and 6-thioguanine), no reduction of circulating white blood cells was observed upon administration of cAVTP and tAVTG (Gunnarsdottir et al., 2002)
It remains, however, a preclinical characterisation
however, there are important caveats: - Injection-site reactions: As with any injectable peptide, mild redness, swelling, or irritation at the injection site appear to be the most commonly reported side effects
Furthermore, the anti-oxidative stress effector heme oxygenase 1 (HO-1) was also upregulated (Fig